The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Several colorectal, gastric, pancreatic and liver cancers, a few breast, prostate, renal and endometrial cancers along with occasional skin, ovarian and urothelial cancers exhibited weak to moderate cytoplasmic and/or membranous positivity. Remaining malignant cells were in general negative.
Most malignant cells showed weak to moderate cytoplasmic positivity. A few cases of malignant melanomas, hepatocellular carcinomas and occasional pancreatic malignancies exhibited strong staining. Several cases of renal, urothelial, lung, uterine cervix cancers, malignant lymphomas and gliomas were negative.
Validation
Two (or more) antibodies yielding similar or partly similar staining patterns which are partly consistent with or contradicted by limited gene/protein characterization data
Two (or more) antibodies yielding similar or partly similar staining patterns which are partly consistent with or contradicted by limited gene/protein characterization data
